According to Zachary Brennan’s story on Endpoints (here), Sally Choe will be leaving OGD in two weeks coinciding with the end of GDUFA II and the beginning of GDUFA III. The interim Director will be Susan Rosencrance “who’s currently director of the FDA’s Office of Lifecycle Products in the Office of Pharmaceutical Quality and has over 30 years of experience at FDA/CDER, including over 24 years in OGD.” I worked with Susan when I was at OGD in various positions and in her roles after I left the Agency. She is a bright star at OGD and has continued to shine in every position of greater responsibility she has taken in her long FDA career.
The search is on for a new permanent Director with no timeline projected for filling the position.
We wish Sally continued success in her next endeavor, which sounds like it will be out of the Agency.
